Why Bicycle Therapeutics plc’s (BCYC) Stock Is Up 5.93%
As of Thursday, October 29, Bicycle Therapeutics plc’s BCYC share price has surged by 5.93%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Commentary & Analysis
What You Need to Know About Bicycle Therapeutics plc's Q4 Earnings
Bicycle Therapeutics plc's fiscal Q4 earnings report was released on Thursday, October 29. Let's dive in to see if (BCYC) missed or beat analyst's expectations.Rosalio Madrigal
Why Bicycle Therapeutics plc’s (BCYC) Stock Is Down 5.36%
As of Friday, October 23, Bicycle Therapeutics plc’s BCYC share price has dipped by 5.36%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Bicycle Therapeutics plc’s (BCYC) Stock Is Down 6.03%
As of Tuesday, October 06, Bicycle Therapeutics plc’s BCYC share price has dipped by 6.03%, which has investors questioning if this is right time to buy.Michael Rose
Why Bicycle Therapeutics plc’s (BCYC) Stock Is Up 10.06%
As of Monday, October 05, Bicycle Therapeutics plc’s BCYC share price has surged by 10.06%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | BCYC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $243.9 | $214.3 | 30% |
|
| Shares Out (Mil) | 70.0 | 53.9 | 55% |
|
| Institutional Ownership | 96.8% | 92.9% | 71% |
|
| Float (Mil) | 7.8 | 41.4 | 16% |
|
| Beta | 1.61 | 0.96 | 85% |
|
| Avg Daily Volume (000s) | 389 | 506 | 54% |
|
| Price Change (52-week) |
(49.4%) | 43.9% | 20% |
|
| Growth | BCYC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 47.5% | 13.2% | 95% |
|
| Net Income (5yr) | (33.8%) | (10.1%) | 12% |
|
| EPS (5yr) | (3.5%) | 15.8% | 27 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (29.1%) | (15.7%) | 20% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 9 | |
| Current EPS | ($0.526) | ($2.260) | ($2.324) | |
| Month Ago EPS | ($0.408) | ($2.454) | ($2.224) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 2 | 0 | 0 | |
| Three Months Ago EPS | ($0.404) | ($2.613) | ($2.219) | |
| Year/Year Chg | 250.7% | (28.5%) | (22.0%) | |
| Financials | BCYC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $84 | $37 | 24% |
|
| Net Income (TTM) (Mil) | ($142) | ($44) | 9% |
|
| EPS (TTM) | ($2.034) | ($1.500) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($175) | ($34) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($179) | $1 | 11% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | ($202) | $172 | 0% |
|
| Valuation | BCYC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.48 | 2.00 | 10% |
|
| P/E | na | 18.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | BCYC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (96.4%) | 67.3% | 2% |
|
| Net Margin | (169.8%) | (63.5%) | 5% |
|
| ROA | (21.3%) | (47.5%) | 20% |
|
| ROE | (25.2%) | (53.3%) | 21% |
|
| Liabilities to Assets | 10.9% | 29.6% | 6% |
|
| F-Score | 4 | 2 | 33% |
|
Bicycle Therapeutics plc did not pass any screens on 11/5/2026.
